louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02067598: Effects of Scapular Exercise on Patients With Scapulocostal Syndrome
Official title: Effects of Scapular Exercise on Patients With Scapulocostal Syndrome
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Scapular Pain
Keywords: Scapular exercises
Lead sponsor: Mae Fah Luang University Hospital
Sponsor class: OTHER
First posted: 2014-02-20
Enrollment: 36
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine the effect of scapular exercise on pain related parameters including pain intensity, 24 hours pain intensity, pressure pain threshold, anxiety and muscle tension in patients with scapulocostal syndrome.


Eligibility criteria: Inclusion Criteria:

1. Male or female
2. Age between 18 - 50 years old
3. The participants have experienced spontaneous scapular pain for longer than 12 weeks (chronic) and that at least one trigger point will be present in the scapular region (serratus posterior superior, rhomboid groups, levator scapulae and trapezius muscles). Trigger points will be diagnosed as the presence of focal tenderness in a taut band and with pain recognition (Chatchawan et al., 2005; Tough et al., 2007).
4. The participants will be able to follow instructions.
5. Good communication and cooperation.

Exclusion Criteria:

1. A history of the following diseases or disorders:

* Rotator cuff disease
* Cervical radiculopathy
* Degenerative shoulder joint disease
* Adhesive capsulitis of shoulder

Primary outcomes:
measure: Pressure Pain Threshold as a measure by algometry
timeFrame: 6 Weeks
Secondary outcomes:
measure: Pain scores on visual analog scale
timeFrame: 6 weeks
measure: Muscle tension on visual analog scale
timeFrame: 6 weeks
measure: Anxiety on State Anxiety Inventory
timeFrame: 6 weeks
measure: 24 hours pain intensity on Visual analog scale
timeFrame: 6 weeks
Other outcomes:
Locations:
city: Mueang
country: Thailand
facility: School of Health Science, Mae Fah Luang University
state: Chiang Rai
Study officials:
References:
Clinical trial NCT06749145: Deep Learning Enhanced Detection of Aortic Stenosis - The DETECT-AS-Diagnostic Study
Official title: Deep Learning Enhanced Detection of Aortic Stenosis - The DETECT-AS-Diagnostic Study
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Aortic Stenosis
Keywords: aortic stenosis
artificial intelligence
Lead sponsor: Yale University
Sponsor class: OTHER
Collaborators: name: National Institute on Aging (NIA)
name: Icahn School of Medicine at Mount Sinai
name: The Methodist Hospital Research Institute
First posted: 2024-12-27
Enrollment: 410
Sex: ALL
Minimum age (years): 70
Standard ages: OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: The DETECT-AS Diagnostic Study will assess the performance of artificial intelligence (AI) risk predictions to detect aortic stenosis using results from portable electrocardiogram (ECG) and cardiac ultrasound devices.


Eligibility criteria: Inclusion Criteria:

* Age 70 years or older
* Attending a routine outpatient primary care clinic at one of the three enrollment sites

Exclusion Criteria:

* Opted out of research studies
* Non-English speaking
* Urgent or emergent visits, defined as a visit for an illness or injury that needs attention quickly or is life-threatening
* Any echocardiogram within 12 months of clinic visit
* Prior history of moderate or severe AS
* Prior history of aortic valve replacement or repair, including transcatheter and surgical AVR with either a bioprosthetic or mechanical valve
* Presence of implantable cardiac devices, including permanent cardiac pacer, implantable cardioverter-defibrillator, or left ventricular assist device
* Prior heart transplant
* History of dementia
* Documented life expectancy of \<1 year or current participation in hospice services.

Primary outcomes:
measure: Number of participants diagnosed with advanced aortic stenosis (AS) by transthoracic echocardiogram (TTE)
timeFrame: Until 12 months from the baseline visit
Secondary outcomes:
Other outcomes:
Locations:
city: Santa Clara
country: United States
facility: Santa Clara Medical Center - Kaiser Permanente
state: California
city: New Haven
country: United States
facility: Yale New Haven Health System
state: Connecticut
city: New York
country: United States
facility: Icahn School of Medicine at Mount Sinai
state: New York
Study officials:
affiliation: Yale University
name: Rohan Khera, MD, MS
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00700245: The Effect of Acute and Chronic Exercise at the Metabolic Syndrome and Markers of Inflammation in Obese Subjects
Official title: The Effect of Acute and Chronic Exercise at the Metabolic Syndrome and Markers of Inflammation in Obese Subjects
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Obesity
Healthy
Keywords: Obese
Adults
Lead sponsor: Aarhus University Hospital
Sponsor class: OTHER
First posted: 2008-06-18
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The human adipose and muscle -tissue produce and release a number of bioactive proteins which contributes to the chronic low grade of inflammatory status which is associated with obesity and plays an important role in the pathogenesis of type 2 diabetes and cardiovascular diseases.

Study 1: Our aim is to investigate if exercise has independent and additive effects in combination with diet-induced weight loss on circulating levels of inflammatory markers and mRNA levels in subcutaneous adipose tissue (SAT) and skeletal muscle tissue (SM.

Study 2: Our aim is to investigate whether gender and weight status plays a role in the metabolic response during two hours of acute exercise


Eligibility criteria: Inclusion Criteria:

* Age 18-45 years,
* obese (30 kg/m2 \< BMI \< 40 kg/m2) physically inactive (\<30 minutes pr. day)
* and weight stabile for at least three months (± 2 kg of current body weight)

Exclusion Criteria:

* cardiovascular disease,
* type 2 diabetes, pregnancy or orthopaedic difficulties causing inability to undertake an exercise program

Primary outcomes:
measure: Changes in inflammatory markers as Adiponectin, MCP-1, Interleukin-6 and CRP. Moreover changes in body composition quantified with MRI
timeFrame: 8 weeks and 12 weeks
measure: Change in Interleukin-6 and other inflammatory markers in plasma, adipose tissue and muscle tissue
timeFrame: 60, 120 240 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Aarhus
country: Denmark
facility: Department of Medicine and Endocrinology C
Study officials:
References:
Clinical trial NCT00344045: Study to Evaluate The Analgesic Efficacy and Safety of Intravenous Paracetamol in Subjects With Postoperative Pain After Total Hip Arthroplasty
Official title: A Phase IV, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Analgesic Efficacy And Safety of IV Paracetamol Versus Placebo in Subjects With Postoperative Pain After Total Hip Arthroplasty
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Pain
Keywords: Subjects with postoperative pain after Total Hip Arthroplasty
Lead sponsor: Bristol-Myers Squibb
Sponsor class: INDUSTRY
First posted: 2006-06-26
Enrollment: 86
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The main purpose is to evaluate the analgesic efficacy of 1g of intravenous (Iv) paracetamol versus i.v. placebo, administered every 6h, as measured by the reduction of the 24-hour cumulative dose of the opioid tramadol in the treatment of postoperative pain following total hip arthroplasty.


Eligibility criteria: Inclusion Criteria:

* Spinal anesth
* BMI 10-35
* No pain conditions/concom med may alter pain quantif.

Exclusion Criteria:

* Other add. surgery
* Liver/Renal function altered
* coagulation alterations
* Respir / Cardiac insufficiency
* Agents affecting microsomal syst

Primary outcomes:
measure: 24-hour cumulative dose of tramadol
timeFrame: 24 hours, defining TO as the start time of the first dose of study drug
Secondary outcomes:
measure: Sum of tramadol and Boluses number, Time from study drug start to tramadol start, total opioid use, Pain intensity scores/diff. from baseline, Global efficacy evaluation, Number of AE, Sedation level, Nausea/Vomiting, Antiemetic needs.
timeFrame: 24 hours, defining TO as the start time of the first dose of study drug
Other outcomes:
Locations:
city: Alcorcon
country: Spain
facility: Local Institution
city: Barcelona
country: Spain
facility: Local Institution
city: Madrid
country: Spain
facility: Local Institution
city: Madrid
country: Spain
facility: Local Institution
city: Vizcaya
country: Spain
facility: Local Institution
Study officials:
affiliation: Bristol-Myers Squibb
name: Bristol-Myers Squibb
role: STUDY_DIRECTOR
References:
Clinical trial NCT07024745: PrEP US NoW: PrEP Utilization Through Increasing Social Capital Among YBMSM Networks With Women
Official title: PrEP US NoW: PrEP Utilization Through Increasing Social Capital Among YBMSM Networks With Women
Study type: INTERVENTIONAL
Overall status: ENROLLING_BY_INVITATION
Phase: NA
Conditions: PrEP Uptake
Lead sponsor: University of Alabama at Birmingham
Sponsor class: OTHER
Collaborators: name: National Institute of Mental Health (NIMH)
First posted: 2025-06-17
Enrollment: 66
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This project is a randomized intervention looking at PrEP uptake among young, black men who identify as gay, bisexual, or same gender loving, utilizing black females within the community to help deliver study related topics. All participants will download the Us\*Now mHealth app that was created specifically for this project. Participants randomized to the Intervention arm will interact with the Us\*Now mHealth app and will be invited to attend 4 weekly sessions led by a black female facilitator where the topic are pre-selected by the study team. Participants randomized to the Control arm will interact with the Us\*Now mHealth app only.


Eligibility criteria: Inclusion Criteria:

* Female Facilitators: 1) Black/African American; 2) age 18-80 years old; 3) Female; 4) able to lead weekly sessions with participants; 5) able to download the Us\*Now mHealth app
* Participants: 1) Black/African American; 2) age 18-29 years old; 3) Male; 4) Identifies as gay, bisexual, or same gender loving; 5) able to download the Us\*Now mHealth app

Exclusion Criteria:

* Female Facilitators: 1) does not identify as Black/African American; 2) not Female; 3) not able to lead the weekly sessions or attend the study training
* Participants: 1) does not identify as Black/African American; 2) age 30 years or older; 3) Identifies as Straight or Heterosexual; 4) not able to download the Us\*Now mHealth app

Primary outcomes:
measure: Intervention Feasibility and Acceptability
timeFrame: 6 months
measure: Change in Social Capital and Internalized Homonegativity
timeFrame: 6 months
Secondary outcomes:
measure: PrEP uptake
timeFrame: 6 months
measure: Change in sexual practices
timeFrame: 6 months
Other outcomes:
Locations:
city: Birmingham
country: United States
facility: University of Alabama at Birmingham
state: Alabama
Study officials:
References:
Clinical trial NCT01407445: Effects of Tribulus Terrestris on Sexual Function in Post-menopausal Women
Official title: Study of the Effects of Tribulus Terrestris on Sexuality in Postmenopausal Women
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Sexual Functions and Problems in the Adult
Keywords: Menopause
Sexual dysfunction
Tribulus
Sexuality
Phytotherapeutic Drugs
Lead sponsor: Faculdade de Ciências Médicas da Santa Casa de São Paulo
Sponsor class: OTHER
Collaborators: name: Fundação de Amparo à Pesquisa do Estado de São Paulo
First posted: 2011-08-02
Enrollment: 60
Sex: FEMALE
Minimum age (years): 40
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Objective: To study the effects of Tribulus terrestris on sexuality in postmenopausal women.

Detailed description: Sexuality is an integral part of every personality, influence thoughts, feelings, actions, integrations, and therefore the physical and mental health. It is estimated that 43% of women have at least one complaint of sexual problem. Disorders of desire and arousal are among the most common problems found in gynecologic practice. Medicinal plants have been used for therapeutic purposes for thousands of years, and aphrodisiac properties described in several plants. Tribulus terrestris is a plant indigenous to India, recommended in the treatment of infertility, low libido and impotence, and its main active ingredient protodioscin (PTN).

Eligibility criteria: Inclusion Criteria:

* Women past menopause, with full autonomy, at least one year of amenorrhea and FSH\> 30 mIU / mL.
* Sexually active
* Partner is stable and without sexual difficulties
* Carrier sexual abuse (desire, arousal, orgasm and dyspareunia)

Exclusion Criteria:

* Women on hormone therapy within the preceding 12 months
* Women without sexual activity
* With diabetes mellitus
* Patients with cognitive impairment
* Patients with hormone-dependent tumor
* History of psychiatric illness
* Patients with liver disease
* Patients with kidney disease
* Users of drugs with proven to decrease sexual desire
* Cardivascular disease, renal disease.

Primary outcomes:
measure: Sexual function in post-menopausal women
timeFrame: 90 days
Secondary outcomes:
measure: Female Intervention Efficacy Index (FIEI)
timeFrame: 3 months
Other outcomes:
Locations:
city: Sao Paulo
country: Brazil
facility: Santa Casa of Sao Paulo Medical School
Study officials:
affiliation: Faculdade de Ciências Médicas da Santa Casa de São Paulo
name: Sonia lima, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00929045: Growth Hormone and Insulin Growth Factor 1 Deficiencies in Children/Adolescents Following Traumatic Brain Injury: The Impact on Growth and Neuropsychological Development
Official title: Growth Hormone and Insulin Growth Factor 1 Deficiencies in Children/Adolescents Following Traumatic Brain Injury: The Impact on Growth and Neuropsychological Recovery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: EARLY_PHASE1
Conditions: Traumatic Brain Injury
Keywords: Growth Hormone replacement
subject 8 to 21
moderate to severe traumatic brain injury
growth hormone deficient
Lead sponsor: University of Virginia
Sponsor class: OTHER
Collaborators: name: Virginia Commonwealth University
name: National Institutes of Health (NIH)
First posted: 2009-06-26
Enrollment: 8
Sex: ALL
Minimum age (years): 8
Maximum age (years): 21
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to look at the relationship between growth hormones, and recovery from a TBI - traumatic brain injury. It is believed that a TBI may interfere with the body's ability to produce growth hormones. These hormones may be needed by the body for growth, mental development and sexual maturation.


Eligibility criteria: Inclusion Criteria:

* This is Phase II trial-subjects have already completed Phase I.
* Traumatic brain injury (TBI).
* Results of the blood work from Phase I shows that your growth hormone levels are low.

Exclusion Criteria:

* Have not completed Phase I of the study.

Primary outcomes:
measure: Neurocognitive changes following moderate/severe TBI
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01754545: Prophylactic Plasma Infusion Therapy for Congenital Thrombotic Thrombocytopenic Purpura
Official title: Prophylactic Plasma Infusion Therapy for Congenital Thrombotic Thrombocytopenic Purpura
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE4
Conditions: Purpura, Thrombotic Thrombocytopenic
Keywords: Infusions, Intravenous
Plasma
ADAMTS-13 protein, human
Lead sponsor: St. Olavs Hospital
Sponsor class: OTHER
Collaborators: name: Norwegian University of Science and Technology
First posted: 2012-12-21
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: PREVENTION

Brief summary: Congenital thrombotic thrombocytopenic purpura (TTP), also called Upshaw-Schulman Syndrome or hereditary or familial TTP is a rare, but severe disease. The purpose of this study is to determine how infusions of plasma to patients with congenital TTP correlate with symptoms and signs of activity of the disease, and to determine why some patients need more frequent infusions of plasma than others to prevent acute attacks of the disease.

Detailed description: Patients with congenital TTP have an inherited lack of function or amount of a protein in plasma called ADAMTS13, that otherwise is responsible for cleaving large von Willebrand-molecules into smaller parts. The patients suffer recurrent attacks of clotting of small blood vessels, that can cause damage to major organs, including the central nervous system. Acute attacks can be treated successfully with infusions of human plasma, and some patients also receive regular plasma therapy for prevention of acute attacks. A small group of patients receive preventive plasma infusions twice or more weekly, indicating a much higher need for plasma than what is otherwise recommended for preventive therapy. Do these patients have an ongoing activity of their disease despite a stimulus? Or a higher turn-over of transfused ADAMTS13? Have these patients developed antibodies against transfused ADAMTS13? Are any symptoms correlated with signs of disease activity?

Eligibility criteria: Inclusion Criteria:

* Confirmed diagnosis of congenital TTP
* On regular prophylactic plasma treatment: \> Once weekly (group 1) or \>1 \<3 times monthly (group 2)
* Between 18 and 65 years
* Capable of understanding and complying with the protocol

Exclusion Criteria:

* Pregnancy
* Acute bout of TTP requiring daily plasma infusions or -exchange for more than 3 days, within the last 2 weeks before intervention period

Primary outcomes:
measure: A composite score of clinical and biochemical signs of disease activity
timeFrame: 4 hours and 24 hours after intervention
Secondary outcomes:
measure: ADAMTS13 activity half-life
timeFrame: 4 hours and 24 hours after intervention
measure: ADAMTS13 allo-antibodies
timeFrame: At baseline
Other outcomes:
Locations:
Study officials:
affiliation: St. Olavs Hospital
name: Anne S von Krogh, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05433545: Adherence to Physiotherapy Scoliosis Specific Exercises in Adolescents With Spine Deformity: Development of a New Questionnaire
Official title: Adherence to Physiotherapy Scoliosis Specific Exercises in Adolescents With Spine Deformity: Development of a New Questionnaire
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Adherence, Treatment
Spinal Deformity
Lead sponsor: Istituto Scientifico Italiano Colonna Vertebrale
Sponsor class: OTHER
First posted: 2022-06-27
Enrollment: 600
Sex: ALL
Minimum age (years): 10
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adolescents with spinal deformity treated with Physiotherapy Scoliosis Specific Exercises

Brief summary: This study aims to develop a new instrument capable of providing an efficient measure of the quality and quantity of adherence to Physiotherapy Scoliosis Specific Exercises performed at home by growing patients with spinal deformity undergoing conservative treatment at a specialized institution. The development of a questionnaire in a Rasch environment and specifically developed for this population will ensure greater sensitivity and specificity of the questionnaire.


Eligibility criteria: Inclusion Criteria:

* aged between 10 and 18 years
* adolescent idiopathic scoliosis of 10 ° Cobb or more
* Scheuermann's kyphosis or idiopathic hyperkyphosis
* prescription of specific exercises

Exclusion Criteria:

* positive neurological evaluation

Primary outcomes:
measure: Adherence to Physiotherapy Scoliosis Specific Exercises
timeFrame: through study completion, an average of 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Milan
country: Italy
facility: ISICO
state: Mi
Study officials:
affiliation: Istituto Scientifico Italiano Colonna Vertebrale
name: Massimiliano Vanossi, PT
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02827045: Study of a Vestibular Biomarker of Phase in Bipolar Disorder
Official title: Exploratory Study of a Vestibular Biomarker of Phase in Bipolar Disorder
Study type: OBSERVATIONAL
Overall status: ENROLLING_BY_INVITATION
Conditions: Bipolar Disorder
Depression, Bipolar
Lead sponsor: Vest Brain,Centro de Estudios Neurovestibulares
Sponsor class: OTHER
First posted: 2016-07-11
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CROSSOVER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: study population come from psychiatric care consults

Brief summary: Bipolar Disorder show cyclic changes of mood between depression (depressive phase) and mania (maniac phase). Vestibular tests have been shown high sensibility and specificity as a biological marker for major depression. This exploratory investigation will measure and compare the vestibular activity of bipolar disorder patients during different phases ( 6 depressed phase, 6 maniac phase, 6 euthimic and 6 control healthy subjects).


Eligibility criteria: Inclusion Criteria:

* Bipolar disorder I or II
* depressive phase of bipolar disorder
* maniac phase of bipolar disorder
* euthimic phase of bipolar disorder

Exclusion Criteria:

* drugs addiction
* alcohol addiction
* neurologic condition, disorder

Primary outcomes:
measure: Vestibular test
timeFrame: December 2017
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References: